Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trial

Disc Medicine announced that its experimental therapy for a rare condition that makes sun exposure painful has completed a Phase 3 study.

The trial reported success on every primary and secondary endpoint, indicating the drug achieved its intended efficacy and safety goals.

The positive outcome follows an earlier FDA rejection of the program, offering the company a potential path to regulatory approval and market entry.

Disc Medicine plans to use the data to file for approval and resume investor confidence in the near future.